TL;DR
This study identifies a novel interaction between the precursor microRNA hsa-let-7a-2 and the Angiotensin II Type 2 Receptor (AGTR2). This interaction, occurring at the receptor's intracellular third loop, leads to the negative regulation of AGTR2 signaling, impacting cellular functions like proliferation, migration, and apoptosis, as well as vascular tone.
What Problem Does This Paper Address?
G protein-coupled receptors (GPCRs) are crucial drug targets, and their functions are modulated by various intracellular partners. While some microRNAs (miRNAs) are known to act as extracellular ligands for certain receptors (like Toll-like receptor 7), their role as intracellular interactors with GPCRs, particularly the protective Angiotensin II Type 2 Receptor (AGTR2), remained largely unexplored. AGTR2 plays a significant role in cardiovascular health, and understanding its regulatory mechanisms is vital. This paper addresses the question of whether miRNAs can directly interact with AGTR2 inside the cell and, if so, how this interaction influences AGTR2's signaling pathways and downstream effects.
Methods
The researchers employed a multi-pronged approach to identify and characterize the interaction between hsa-let-7a-2 and AGTR2:
- Infrared-UV-C crosslinking immunoprecipitation (irCLIP) and RNA-sequencing: This technique was used to globally identify RNAs that bind to AGTR2.
- RNA-binding protein immunoprecipitation (RIP) followed by RT-PCR: This was used to confirm the binding of specific miRNAs and pre-miRNAs to AGTR2.
- Chromatin Isolation by RNA Purification (ChIRP) and RNA Pull-down Assays: These methods were used to specifically isolate and confirm the binding of hsa-let-7a-2 to AGTR2.
- Microscale Thermophoresis (MST) Assay: This technique was employed to investigate the kinetic characteristics of hsa-let-7a-2 binding to AGTR2, including determining dissociation coefficients (KD) and assessing competitive binding.
- Competitive Inhibition Assays (Radioligand and Fluorescent Ligand Binding): These assays were used to determine the nature of the binding (competitive vs. non-competitive) between hsa-let-7a-2 and AGTR2.
- In vitro loop peptide binding assays: Synthetic peptides representing different loops of AGTR2 were used to pinpoint the specific binding site of hsa-let-7a-2.
- Gain-of-function and Loss-of-function studies: Overexpression and knockdown of hsa-let-7a-2 were performed in various cell lines (including knockout models for AGTR1, AGTR2, and Dicer) to assess its impact on AGTR2 signaling pathways (cAMP levels, SHP-1 activity, RhoA phosphorylation) and cellular functions (proliferation, migration, apoptosis).
- In vivo studies: Experiments using mouse mesenteric arteries were conducted to evaluate the effect of hsa-let-7a-2 on AGTR2-mediated vasodilation and signaling.
Datasets
Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and animal models.
Key Insights and Ideas
- Pre-miRNA as a direct AGTR2 interactor: The most striking finding is that not just mature miRNAs, but specifically the precursor form, hsa-let-7a-2, directly binds to AGTR2. This challenges the typical understanding of miRNAs acting solely in their mature form.
- Specific binding site identified: Hsa-let-7a-2 preferentially binds to the intracellular third loop of AGTR2, a region critical for the receptor's interaction with G proteins and other signaling molecules. This suggests a direct interference mechanism.
- Non-competitive binding: Hsa-let-7a-2 binds to AGTR2 in a non-competitive manner with Angiotensin II, implying a distinct binding site or mechanism compared to the primary ligand.
- Negative regulation of AGTR2 signaling: Overexpression of hsa-let-7a-2 suppresses key AGTR2-mediated signaling events, including reduced cAMP levels, inhibited SHP-1 activity, and decreased RhoA phosphorylation. Conversely, its knockdown enhances these effects.
- Impact on cellular functions: The interaction of hsa-let-7a-2 with AGTR2 significantly influences cellular processes, inhibiting Ang II-induced proliferation and migration while promoting apoptosis.
- Vasodilation modulation: In vivo experiments demonstrate that hsa-let-7a-2 overexpression reduces AGTR2-dependent vasodilation, further highlighting its regulatory role.
- Structure-specific binding: The binding of hsa-let-7a-2 to AGTR2 appears to be structure-specific rather than sequence-specific, as no conserved RNA-binding domain was found on AGTR2.
Key Results
- Hsa-let-7a-2 was identified as a specific binding partner of AGTR2 using irCLIP and RIP assays.
- MST and competitive binding assays revealed that hsa-let-7a-2 binds to AGTR2 non-competitively with Ang II, with KD values in the nanomolar range.
- Hsa-let-7a-2 was found to bind to the intracellular third loop of AGTR2.
- Overexpression of hsa-let-7a-2 significantly suppressed Ang II-induced cAMP lowering, RhoA inhibition, and SHP-1 activation in various cell models.
- Hsa-let-7a-2 overexpression reversed Ang II-induced antiproliferation, antimigration, and proapoptosis in Dicer-/-AGTR1-/- cells.
- In vivo studies showed that hsa-let-7a-2 overexpression reduced AGTR2-dependent vasodilation in mouse mesenteric arteries.
Limitations and Future Work
- Specificity of binding: While hsa-let-7a-2 was shown to bind AGTR2, the study notes that the binding is likely structure-specific, not sequence-specific, due to the lack of a conserved RNA-binding domain on AGTR2. Further investigation into the precise structural determinants of this interaction could be beneficial.
- In vivo relevance: While in vivo studies were conducted on mesenteric arteries, exploring the broader physiological implications of this interaction in different tissues and disease models would be valuable.
- Mechanism of pre-miRNA processing: The study highlights that hsa-let-7a-2 is a precursor miRNA. Further research could delve into how this interaction might influence the processing of hsa-let-7a-2 into its mature forms (hsa-let-7a-5p and hsa-let-7a-2-3p) or if the pre-miRNA form has independent functions beyond its role as a precursor.
- Therapeutic potential: The findings suggest that modulating the hsa-let-7a-2/AGTR2 interaction could be a therapeutic strategy for cardiovascular diseases. Future work could explore the development of small molecules or other interventions to target this interaction.
Summary updated